Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Quizartinib”

39 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 39 results

Very early researchStudy completedNCT04459585
What this trial is testing

The Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants

Who this might be right for
Healthy SubjectsDrug-drug InteractionPharmacokinetics+1 more
Daiichi Sankyo Co., Ltd. 20
Early research (Phase 1)Study completedNCT01390337
What this trial is testing

Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

Who this might be right for
Leukemia, Myeloid, Acute
Daiichi Sankyo 19
Testing effectiveness (Phase 2)Ended earlyNCT04209725
What this trial is testing

CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

Who this might be right for
Leukemia, Myeloid, Acute
SCRI Development Innovations, LLC 1
Early research (Phase 1)Study completedNCT02834390
What this trial is testing

Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Daiichi Sankyo Co., Ltd. 7
Testing effectiveness (Phase 2)UnknownNCT03135054
What this trial is testing

Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD

Who this might be right for
AMLFLT3-ITD Mutation
The University of Hong Kong 40
Testing effectiveness (Phase 2)Study completedNCT04687761
What this trial is testing

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

Who this might be right for
Leukemia, Myeloid, AcuteDe NovoAge More 60yr
PETHEMA Foundation 113
Early research (Phase 1)Looking for participantsNCT05735184
What this trial is testing

Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Who this might be right for
Acute Myeloid LeukemiaMixed Lineage Leukemia Gene MutationRefractory AML+7 more
Kura Oncology, Inc. 420
Early research (Phase 1)Study completedNCT02675478
What this trial is testing

Phase 1 Study of Quizartinib

Who this might be right for
Relapsed AMLRefractory AML
Daiichi Sankyo Co., Ltd. 17
Testing effectiveness (Phase 2)Study completedNCT04107727
What this trial is testing

Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
PETHEMA Foundation 273
Large-scale testing (Phase 3)WithdrawnNCT04676243
What this trial is testing

Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML

Who this might be right for
Acute Myeloid Leukemia
University Hospital Heidelberg
Early research (Phase 1)Ended earlyNCT04477291
What this trial is testing

CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Aptose Biosciences Inc. 45
Testing effectiveness (Phase 2)Study completedNCT02984995
What this trial is testing

Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

Who this might be right for
Leukemia, Myeloid, Acute
Daiichi Sankyo Co., Ltd. 37
Large-scale testing (Phase 3)Looking for participantsNCT06578247
What this trial is testing

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

Who this might be right for
Leukemia
Daiichi Sankyo 700
Large-scale testing (Phase 3)Study completedNCT02668653
What this trial is testing

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid LeukemiaLeukemia
Daiichi Sankyo 539
Early research (Phase 1)Ended earlyNCT03552029
What this trial is testing

Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Daiichi Sankyo 10
Testing effectiveness (Phase 2)Ended earlyNCT03989713
What this trial is testing

Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD

Who this might be right for
AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed After First Line Treatment)
Prof. Dr. Richard F Schlenk 11
Not applicableNo Longer AvailableNCT03746912
What this trial is testing

Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib

Who this might be right for
Acute Myeloid Leukemia With Gene Mutations
Daiichi Sankyo
Early research (Phase 1)Study completedNCT04473664
What this trial is testing

Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment

Who this might be right for
Hepatic ImpairmentModerate Impaired Hepatic Function
Daiichi Sankyo 12
Testing effectiveness (Phase 2)Looking for participantsNCT04047641
What this trial is testing

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaBlasts 20 Percent or More of Bone Marrow Nucleated CellsHigh Risk Myelodysplastic Syndrome+5 more
M.D. Anderson Cancer Center 80
Early research (Phase 1)Study completedNCT06772246
What this trial is testing

Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate

Who this might be right for
Healthy Subjects
Daiichi Sankyo 70
Load More Results